申请人:——
公开号:US20020156069A1
公开(公告)日:2002-10-24
Selective MMP-13 inhibitors are benzo thiadiazines of the Formula
1
or a pharmaceutically acceptable salt thereof, wherein R
2
is hydrogen or alkyl; R
1
and R
3
include hydrogen, alkyl, and aryl, with the proviso that R
3
is not (CH
2
)
m
biphenyl or (CH
2
)
m
substituted biphenyl; X is O or NH, n is 0, 1, or 2. The compounds of Formula I, or a pharmaceutically acceptable salt thereof, is useful for treating diseases mediated by an MMP-13 enzyme, including diseases selected from osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure.
选择性MMP-13抑制剂是公式1中的苯并噻二唑或其药学上可接受的盐,其中R2是氢或烷基;R1和R3包括氢,烷基和芳基,但有条件是R3不是(CH2)m联苯或(CH2)m取代联苯;X是O或NH,n为0、1或2。公式I中的化合物或其药学上可接受的盐对于治疗由MMP-13酶介导的疾病有用,包括骨关节炎、类风湿性关节炎、癌症、炎症和心力衰竭等疾病。